Episode 3: Screening for NAFLD and NASH

Overview

In this podcast, AGA Institute’s NASH: Take Action! Steering Committee members talk to global leaders in gastroenterology, hepatology, endocrinology and primary care about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. In this episode we’re talking about screening people for non-alcoholic fatty liver disease in the primary care setting.

Learning Objectives

By the end of this podcast, listeners will be able to:

Describe risk factors and risk stratification for NASH
Discuss criteria for screening patients at high risk for NASH
Understand screening methods for NAFLD and NASH
Describe emerging screening tools

Key Takeaways

Patients who are obese, over 50, have type 2 diabetes, and/or have two or more factors associated with the metabolic syndrome should be screened for NAFLD/NASH.
Primary care providers can use results of basic laboratory blood tests and patient age to begin stratifying risk of NAFLD-related liver fibrosis.
Results of noninvasive tests to assess liver stiffness can be used to further stratify risk once other forms of hepatitis have been ruled out.

CME

To claim credit, visit AGA University. You will need to create a free account to log in and claim your credit.

This activity is accredited through Sep. 30, 2022.

The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians. The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Credits

Hosts: Fasiha Kanwal, MD, Baylor College of Medicine; Kenneth Cusi, MD, University of Florida; Jay Shubrook, DO, Touro University

Guest: Kim Pfotenhauer, DO, Michigan State University; Eugene Wright, MD, Duke University

Created by: Knighten Health, LLC

Produced and edited by: Nick Jaworksi

Cover art: THOR Design Studio

Disclosures

Fasiha Kanwal discloses no conflicts.

Kenneth Cusi has received research support for the University of Florida as principal investigator from Cirius, Echosens, Inventiva, Novo Nordisk, Poxel and Zydus and is a consultant for Allergan, Arrowhead, Astra-Zeneca, Axcella, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, HighTide, Inventiva, Intercept, Ionis, Janssen, Pfizer, Poxel, Prosciento, Madrigal, and Novo Nordisk.

Jay H. Shubrook has served as an advisor to Sanofi, Eli Lilly, Novo Nordisk, Bayer, and MannKind.

Kim Pfotenhauer and Eugene Wright disclose no conflicts.

Sponsor

American Gastroenterological Association

Funding

This podcast series was supported by an independent medical education grant from Novo Nordisk Inc.